Pfizer and Bristol Myers Squibb are facing patent-related challenges, but both drugmakers are developing new medicines. Despite these issues, they are attractively valued with strong dividend programs. Pfizer’s financial results have been unpredictable, but it is addressing challenges with new products and a promising oncology pipeline. Bristol Myers is also overcoming patent cliffs with new approvals like Opdivo Qvantig. Both stocks offer high yields and value for investors.

Read more at Yahoo Finance: 2 High-Yield Dividend Stocks Too Cheap to Ignore